Sarilumab vs SULFASALAZINE

Compare Sarilumab (Kevzara) and SULFASALAZINE (Sulfasalazine) — clinical data, side effects, and patient experiences.

Sarilumab

Kevzara · IL-6 Receptor Inhibitor

How it works

Monoclonal antibody that binds IL-6 receptor, blocking IL-6-mediated inflammatory signalling.

Approved for

Rheumatoid Arthritis

FDA: 2017SubcutaneousInjection

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Quick Comparison

SarilumabSULFASALAZINE

Drug Class

IL-6 Receptor Inhibitor

Aminosalicylate (IBD)

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

2017

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Sarilumab

Drug Not Working

>10%

Joint Pain

1-10%

Condition Worsened

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

1-10%

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

FDA Warnings

Sarilumab

Serious infections
GI perforations
Neutropenia

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Clinical Trial Data

No head-to-head clinical studies found for Sarilumab vs SULFASALAZINE.

Sarilumab vs SULFASALAZINE: What You Should Know

Key Differences

Sarilumab is a IL-6 Receptor Inhibitor, while SULFASALAZINE belongs to the Aminosalicylate (IBD) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. Sarilumab is administered via Subcutaneous, whereas SULFASALAZINE uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

Sarilumab carries 3 FDA warnings. SULFASALAZINE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

BALSALAZIDE DISODIUM vs SULFASALAZINE→MESALAMINE vs SULFASALAZINE→Sarilumab vs TOCILIZUMAB→ADALIMUMAB vs SULFASALAZINE→SULFASALAZINE vs USTEKINUMAB→AZATHIOPRINE vs SULFASALAZINE→

Loading comparison data...

Sarilumab vs SULFASALAZINE

Compare Sarilumab (Kevzara) and SULFASALAZINE (Sulfasalazine) — clinical data, side effects, and patient experiences.

Sarilumab

Kevzara · IL-6 Receptor Inhibitor

How it works

Monoclonal antibody that binds IL-6 receptor, blocking IL-6-mediated inflammatory signalling.

Approved for

Rheumatoid Arthritis

FDA: 2017SubcutaneousInjection

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Quick Comparison

SarilumabSULFASALAZINE

Drug Class

IL-6 Receptor Inhibitor

Aminosalicylate (IBD)

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

2017

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Sarilumab

Drug Not Working

>10%

Joint Pain

1-10%

Condition Worsened

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

1-10%

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

FDA Warnings

Sarilumab

Serious infections
GI perforations
Neutropenia

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Clinical Trial Data

No head-to-head clinical studies found for Sarilumab vs SULFASALAZINE.

Sarilumab vs SULFASALAZINE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.